
This startup wants to build a needle-free CGM using nanotechnology
Graphwear recently raised $20.5 million, which it plans to use to develop a CGM that uses nanotechnology to measure blood glucose levels.
Graphwear recently raised $20.5 million, which it plans to use to develop a CGM that uses nanotechnology to measure blood glucose levels.
The latest round of funding, led by Chinese investors, brings the total amount of money raised by the company, co-founded by CRISPR pioneer Jennifer Doudna, to more than $70 million.
This on-demand webinar will offer insights and share tips on helping practices run more efficiently.
The company said it would use the funding to expand its single-cell DNA sequencing platform into CRISPR applications and global markets.
The company plans to use blockchain and other technologies to develop the genomic data marketplace, under a partnership with Veritas Genetics.